Lynk Pharmaceuticals Achieves Breakthrough Results in Phase III Trial of Zemprocitinib for Atopic Dermatitis Lynk Pharmaceuticals has announced promising topline results from its Phase III trial of zemprocitinib, aimed at treating moderate-to-severe atopic dermatitis, demonstrating significant efficacy and safety.

Lynk Pharmaceuticals Achieves Breakthrough Results in Phase III Trial of Zemprocitinib for Atopic Dermatitis #China #Shanghai #Atopic_Dermatitis #Lynk_Pharmaceuticals #Zemprocitinib

Lynk Pharmaceuticals Reports Encouraging Phase III Results for Zemprocitinib in Rheumatoid Arthritis Treatment Lynk Pharmaceuticals announces positive topline data from Phase III trials of Zemprocitinib, showcasing significant efficacy in patients with rheumatoid arthritis.

Lynk Pharmaceuticals Reports Encouraging Phase III Results for Zemprocitinib in Rheumatoid Arthritis Treatment #China #Hangzhou #rheumatoid_arthritis #Lynk_Pharmaceuticals #Zemprocitinib